These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8242642)

  • 1. Correspondence re: J. P. Alexander et al., T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res., 53: 1380-1387, 1993.
    Whiteside TL
    Cancer Res; 1993 Dec; 53(23):5828. PubMed ID: 8242642
    [No Abstract]   [Full Text] [Related]  

  • 2. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
    Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
    Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
    Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
    Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
    J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
    Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
    Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
    Finke JH; Zea AH; Stanley J; Longo DL; Mizoguchi H; Tubbs RR; Wiltrout RH; O'Shea JJ; Kudoh S; Klein E
    Cancer Res; 1993 Dec; 53(23):5613-6. PubMed ID: 8242613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune suppression in renal cell carcinoma.
    Frankenberger B; Noessner E; Schendel DJ
    Semin Cancer Biol; 2007 Aug; 17(4):330-43. PubMed ID: 17656104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4.
    Obiri NI; Hillman GG; Haas GP; Sud S; Puri RK
    J Clin Invest; 1993 Jan; 91(1):88-93. PubMed ID: 8423237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function.
    Gati A; Guerra N; Giron-Michel J; Azzarone B; Angevin E; Moretta A; Chouaib S; Caignard A
    Cancer Res; 2001 Apr; 61(8):3240-4. PubMed ID: 11309272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma.
    Cardi G; Heaney JA; Schned AR; Phillips DM; Branda MT; Ernstoff MS
    Cancer Res; 1997 Aug; 57(16):3517-9. PubMed ID: 9270022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis.
    Wittnebel S; Da Rocha S; Giron-Michel J; Jalil A; Opolon P; Escudier B; Validire P; Khawam K; Chouaib S; Azzarone B; Caignard A
    Cancer Res; 2007 Jun; 67(12):5594-9. PubMed ID: 17575122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cellular and molecular basis of natural antitumor immunity in renal cell carcinoma patients.
    Schendel DJ; Falk CS; Frankenberger B; Noessner E; Schleypen J; Pohla H
    Urologe A; 2004 Sep; 43 Suppl 3():S133-5. PubMed ID: 15179552
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor microenvironment and immune effector cells: isolation, large scale propagation and characterization of CD8+ tumor infiltrating lymphocytes from renal cell carcinomas.
    Linna TJ; Moody DJ; Feeney LA; Okarma TB; Tso CL; Belldegrun A
    Immunol Ser; 1994; 61():175-8. PubMed ID: 8011741
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
    Frankenberger B; Pohla H; Noessner E; Willimsky G; Papier B; Pezzutto A; Kopp J; Oberneder R; Blankenstein T; Schendel DJ
    Clin Cancer Res; 2005 Mar; 11(5):1733-42. PubMed ID: 15755994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
    Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
    Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are renal cell carcinoma cells able to modulate the cytotoxic effect of tumor infiltrating lymphocytes by secretion of interleukin-6?
    Steiner T; Junker U; Wunderlich H; Schubert J
    Anticancer Res; 1999; 19(2C):1533-6. PubMed ID: 10365139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
    Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
    Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.